Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PRIMIER*: Randomized Phase II Trial of mFOLFOX6/Bevacizumab With or Without PRI-724 as First Line Treatment for Metastatic Colorectal Cancer

NCT02413853 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.

NCT NCT02413853
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02413853 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PRIMIER*: Randomized Phase II Trial of mFOLFOX6/Bevacizumab With or Without PRI-724 as First Line Treatment for Metastatic Colorectal Cancer
Lead sponsor
University of Southern California
Phase
Phase 2
Overall status
Withdrawn
Start date
November 30, 2015
Completion date
November 30, 2018
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal adenocarcinoma, stage iva colorectal cancer, stage ivb colorectal cancer